Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 578.

https://doi.org/10.1182/blood-2024-200271

Published: 2024

Journal Articles

Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study

Ingrid Glimelius, Won Seog Kim, Ewa Paszkiewicz-Kozik, Daniel Ernst, Reid W. Merryman, Claudia Moreira, Sanfang Tu, Yixin Ren, Katherine Ryland, Uzor C. Ogbu, Pier Luigi Zinzani

Blood (2024) 144 (Supplement 1): 4405.

https://doi.org/10.1182/blood-2024-205897

Published: 2024

Journal Articles

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lalita Norasetthada, Joaquin Diaz, Fangfang Lv, Yuqin Song, Seung Tae Lee, Ewa Paszkiewicz-Kozik, Dipenkumar Modi, Armando Santoro, Kumudu Pathiraja, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan

Blood (2024) 144 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2024-201522

Published: 2024

Journal Articles

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Ewa Paszkiewicz-Kozik, Claudia Moreira, Mehmet Turgut, Marcelo Garrido, Ingrid Glimelius, Seung Tae Lee, Yazeed Sawalha, Yixin Ren, Katherine Ryland, Uzor C. Ogbu, Diego Villa

Blood (2024) 144 (Supplement 1): 3025.

https://doi.org/10.1182/blood-2024-205985

Published: 2024

Journal Articles

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Muhit Ozcan, Fangfang Lv, Lalita Norasetthada, Ewa Paszkiewicz-Kozik, Joaquin Díaz Schmidt, Dipenkumar Modi, Alexander Fosså, Sagun Goyal, Won Seog Kim, Seung Tae Lee, Armando Santoro, Mehmet Sonmez, Kumudu Pathiraja, Nishitha Reddy, Patricia Marinello, Yuqin Song

Blood (2023) 142 (Supplement 1): 1720.

https://doi.org/10.1182/blood-2023-186788

Published: 2023

Journal Articles

The Outcome of the First-Line Therapy of Patients with Follicular Lymphoma during COVID-19 Pandemic. a Real-World Data from the Polish Lymphoma Research Group (PLRG)

Blood (2023) 142 (Supplement 1): 1679.

https://doi.org/10.1182/blood-2023-186945

Published: 2023

Journal Articles

Safety and Early Efficacy of Obinutuzumab in Combination with Chemotherapy in Treatment Naive Patients with Follicular Lymphoma - Report of Polish Lymphoma Research Group (PLRG)

Blood (2021) 138 (Supplement 1): 4525.

https://doi.org/10.1182/blood-2021-145534

Published: 2021

Journal Articles

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Pier Luigi Zinzani, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, José S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, DMed Sci, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Monika Raut, Hilde Giezek, Akash Nahar, John Kuruvilla, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139416

Published: 2020

Journal Articles

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

John Kuruvilla, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, Laura Maria Fogliatto, Iara Goncalves, José de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142565

Published: 2020

Journal Articles

Bendamustine, Gemcitabine and Dexamethasone Chemotherapy Is Effective Salvage and Stem-Cell Mobilization Regimen in Patients with Relapsed or Refractory Hodgkin Lymphoma — Early Results of the Polish Lymphoma Research Group Study

Ewa Paszkiewicz-Kozik, Jan Zaucha, MD PhD, Agata Tyczyńska, MD, Marcin Szymanski, MD, Lukasz Targonski, MD, Joanna Drozd-Sokolowska, MD PhD, Elżbieta Wojciechowska-Lampka, MD, Joanna Tajer, MD PhD, Pawel Kurczab, MD, Joanna Romejko-Jarosinska, MD PhD, Michal Osowiecki, MD, Jan Walewski, MD PhD

Blood (2017) 130 (Supplement 1): 4098.

https://doi.org/10.1182/blood.V130.Suppl_1.4098.4098

Published: 2017

Journal Articles

Subcutaneous Compared to Intravenous Administration of Rituximab Plus CHOP in Patients with Diffuse Large B-Cell Lymphoma — a Study By the Polish Lymphoma Research Group

Ewa Paszkiewicz-Kozik, Monika Dlugosz-Danecka, MD PhD, Paweł J. Robak, MD, Elżbieta Wojciechowska-Lampka, MD, Monika Swierkowska-Czeneszew, MD, Joanna Tajer, MD PhD, Joanna Romejko-Jarosinska, MD PhD, Katarzyna Domanska-Czyz, MD, Marcin Szymanski, MD, Marta Morawska, MD, Lukasz Targonski, MD, Michal Osowiecki, MD, Beata Ostrowska, MDPhD, Anna Paulina Dabrowska-Iwanicka, MD PhD, Jan Walewski, MD PhD

Blood (2017) 130 (Supplement 1): 5217.

https://doi.org/10.1182/blood.V130.Suppl_1.5217.5217

Published: 2017

Journal Articles

DA-EPOCH-R Is an Effective Regimen in High Grade B-Cell Lymphoma Defined By Cell-of-Origin, Karyotype and BCL2 / MYC / BCL6 Status and Expression

Blood (2016) 128 (22): 1754.

https://doi.org/10.1182/blood.V128.22.1754.1754

Published: 2016

Journal Articles

Secondary Central Nervous System (CNS) Involvement in Patients Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) during the First Line R-CHOP Treatment and after the End of Treatment

Joanna Romejko-Jarosinska, MD PhD, Michal Osowiecki, MD, Beata Ostrowska, MD PhD, Martyna Kotarska, MD, Katarzyna Domanska-Czyz, MD, Marcin Szymanski, MD, Lukasz Targonski, MD, Anna Borawska, MD PhD, Agnieszka Druzd-Sitek, MD PhD, Ewa Paszkiewicz-Kozik, MD PhD, Lidia Poplawska, Grzegorz Rymkiewicz, MD PhD, Jan Walewski, MD PhDProf

Blood (2015) 126 (23): 5040.

https://doi.org/10.1182/blood.V126.23.5040.5040

Published: 2015

Journal Articles

CHOP-R and High-Dose Methotrexate In The Primary CNS Lymphoma Revisited. 10-Year Experience and 92 Patients From a Single Institution

Beata Ostrowska, Michal Osowiecki, Katarzyna Domanska-Czyz, Joanna Romejko-Jarosinska, Ewa Paszkiewicz-Kozik, Lidia Poplawska, Grzegorz Rymkiewicz, Jaroslaw Stobiecki, Wojciech Michalski, Jan Walewski

Blood (2013) 122 (21): 3051.

https://doi.org/10.1182/blood.V122.21.3051.3051

Published: 2013

Journal Articles

Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma

Jan Walewski, MD, PhD, Ewa Paszkiewicz-Kozik, Agnieszka Warszewska, Gabriela Borsaru, Andreea Moicean, Andrzej Hellmann, Jiri Mayer, MD, PhD, Bernhard Hauns, Anna Mais, Stefan W. Henning, Bernd Hentsch

Blood (2011) 118 (21): 2675.

https://doi.org/10.1182/blood.V118.21.2675.2675

Published: 2011

Journal Articles

Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor.

Jan Walewski, MD, PhD, DSc, Ewa Paszkiewicz-Kozik, MD, Gabriela Borsaru, MD, Andreea Moicean, MD, Agnieszka Warszewska, MD, Klaus Strobel, MD, Alberto Biggi, MD, Bernhard Hauns, MD, Anna Mais, PhD, MSc, Stefan W. Henning, PhD, MSc, Bernd Hentsch, PhD

Blood (2010) 116 (21): 2811.

https://doi.org/10.1182/blood.V116.21.2811.2811

Published: 2010

Journal Articles

Fine Needle Aspiration Biopsy with Flow Cytometry Is a Reliable Method for Defining Immunophenotype of Prognostic Value in T Lymphoblastic Lymphoma.

Beata Ostrowska, Grzegorz Rymkiewicz, Joanna Romejko-Jarosinska, Katarzyna Blachnio, Katarzyna Domanska-Czyz, Wlodzimierz Osiadacz, Michal Osowiecki, Ewa Paszkiewicz-Kozik, Lidia Poplawska, Danuta Rozewska, Jaroslaw Stobiecki, Elzbieta Wojciechowska-Lampka, Wojciech Michalski, Jan Walewski

Blood (2009) 114 (22): 3928.

https://doi.org/10.1182/blood.V114.22.3928.3928

Published: 2009

Journal Articles

Predictive Value of Bcl-2 and Bcl-6 Protein Expression in Diffuse Large B-Cell Lymphoma Patients from a Single Institution.

Ewa Paszkiewicz-Kozik, MD, Olga Mioduszewska, MD PhD, Irena Federowicz, MD PhD, Ewa Kraszewska, Elzbieta Kulczycka, PhD, Katarzyna Domanska-Czyz, MD, Beata Ostrowska, MD, Joanna Romejko-Jarosinska, MD, Michal Osowiecki, MD, Jan A. Walewski, MD PhD

Blood (2004) 104 (11): 4546.

https://doi.org/10.1182/blood.V104.11.4546.4546

Published: 2004

NARROW

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

The Outcome of the First-Line Therapy of Patients with Follicular Lymphoma during COVID-19 Pandemic. a Real-World Data from the Polish Lymphoma Research Group (PLRG)

Safety and Early Efficacy of Obinutuzumab in Combination with Chemotherapy in Treatment Naive Patients with Follicular Lymphoma - Report of Polish Lymphoma Research Group (PLRG)

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Bendamustine, Gemcitabine and Dexamethasone Chemotherapy Is Effective Salvage and Stem-Cell Mobilization Regimen in Patients with Relapsed or Refractory Hodgkin Lymphoma — Early Results of the Polish Lymphoma Research Group Study

Subcutaneous Compared to Intravenous Administration of Rituximab Plus CHOP in Patients with Diffuse Large B-Cell Lymphoma — a Study By the Polish Lymphoma Research Group

DA-EPOCH-R Is an Effective Regimen in High Grade B-Cell Lymphoma Defined By Cell-of-Origin, Karyotype and BCL2 / MYC / BCL6 Status and Expression

Secondary Central Nervous System (CNS) Involvement in Patients Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) during the First Line R-CHOP Treatment and after the End of Treatment

CHOP-R and High-Dose Methotrexate In The Primary CNS Lymphoma Revisited. 10-Year Experience and 92 Patients From a Single Institution

Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma

Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor.

Fine Needle Aspiration Biopsy with Flow Cytometry Is a Reliable Method for Defining Immunophenotype of Prognostic Value in T Lymphoblastic Lymphoma.

Predictive Value of Bcl-2 and Bcl-6 Protein Expression in Diffuse Large B-Cell Lymphoma Patients from a Single Institution.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only